期刊文献+

奥硝唑对大鼠血胰屏障通透性的研究 被引量:4

Permeability of ornidazole through blood-pancreatic barrier in rats
下载PDF
导出
摘要 目的研究奥硝唑对大鼠血胰屏障的通透性,为选择合适的抗微生物药物预防和治疗胰腺组织感染提供理论依据。方法给予大鼠口服奥硝唑20mg/kg,在规定时间点取样,用反相高效液相色谱法(RP-HPLC)测定胰腺组织和血清中药物的浓度。结果血清、胰腺组织中奥硝唑浓度在20m in时最高,分别为(13.24±2.01)mg/L,(18.34±3.26)mg/L。药物对血胰屏障的通透率(PR)在20m in以后一直>1。结论口服奥硝唑后,药物在胰腺中有良好的分布,对血胰屏障具有良好的通透性,值得向临床推荐用于预防和治疗胰腺感染。 OBJECTIVE To investigate the permeability of ornidazole through blood-pancreatic barrier in rats. METHODS Oruidazole (20mg/kg body weight) were fed to rats. At the given time points, the serum and pancreatic tissue samples were collected. The concentrations of oruidazole in the serum and pancreatic tissue were measured by HPLC. RESULTS The concentration - time profiles of oruidazole could be described as two - compartment model in rats; The peak concentrations in serum and pancreatic tissue were 13.24±2.01mg/L, 18.34±3.26mg/L at 20 min respectively. Then the concentrations decreased quickly in all of them. Concentrations in pancreatic tissue were higher than those in serum after 20 min and even at 360 min. The permeation ratio (PR) through blood - pancreatic barrier was higher continuously than 1 after 20 min. CONCLUSION Ornidazole can permeate blood - pancreatic barrier satisfactory, therefore it is worthy of being recommended for prevention and treatment of pancreatic infections.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2006年第5期425-428,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 奥硝唑 血胰屏障 通透率 胰腺炎 omidazole blood-pancreas barrier permeation ratio pancreatitis
  • 相关文献

参考文献13

二级参考文献56

  • 1张臣烈,汤耀卿,袁祖荣,张圣道.急性胰腺炎外科处理方案(1996年修订稿)[J].中国实用外科杂志,1997,17(4):251-252. 被引量:44
  • 2[1]Merdjan H,Bonnat C,Singlas E,et al.Measurement of ornidazole by high performance liquid chromatography.Chromatography,1983;273:475~480.
  • 3[2]Heizmann P,Geschke R,Zinapold K.Determination of omidazole and its main metabolites in biological fluids.Chromatography,1990;534:233~240.
  • 4[3]Martin C,Bruguerolle B,Mallet N,et al.Pharmacokinetics and tissue penetration of a single dose of ornidazole for antibiotic prophylaxis in colorectal surgery.Antimicrobial Agents and Chemotherapy,1990;34:1921~1924.
  • 5[4]Turcant A,Granry J.C.,Allain P,et al.Pharmacokinetics of ornidazole in neonates and infants after a single intravenous infusion.Eur J Clin Pharmcol,1987;32:111~113.
  • 6[1]Lamp KC, Freeman CD, Klutman NE, et al.Pharmaco- kinetics and pharmacodynamics of the nitroimidazole antimicrobials[J].Clin Pharmacokinet,1999,36(5): 353.
  • 7[2]Munoz E, Castella J, Gutierrez JF.In vivo and in vitro sensitivity of Trichomonas gallinae to some nitroimidazole drugs[J].Vet Parasitol,1998,78(4): 239.
  • 8[3]Erenmemisoglu A, Tekol Y, Aydin N.Prophylactic effect of ornidazole on experimental tetanus in mice[J].Drugs Exp Clin Res, 1995,21(2): 59.
  • 9[4]Cedillo- Rivera R, Munoz O.In- vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents[J].J Med Microbiol, 1992,37(3):221.
  • 10[5]Okkan S, Atkovar G, Sahinler I,et al.A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results[J].Br J Cancer Suppl, 1996,27: 282.

共引文献1958

同被引文献20

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部